Drug Trial Radar · NCT03906071
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
577
Actual
Start
Jul 15, 2019
Primary completion
Mar 20, 2023
Study completion Sep 30, 2025
Sponsor
- Lead sponsor
- Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- Bristol-Myers Squibb
- First posted
- Apr 8, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or after platinum-based chemotherapy and checkpoint inhibitor therapy.
Conditions
- Metastatic Non-Squamous Non-Small Cell Lung Cancer
Interventions
NivolumabBiological
Nivolumab is an antibody directed at the programmed death receptor-1 (PD-1), blocking its interaction with PD-L1 and PD-L2.
SitravatinibDrug
Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
DocetaxelDrug
Docetaxel is an anti-neoplastic agent that acts by disrupting the microtubular network in cells.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: From randomization date to date of death due to any cause (Up to approximately 44 months)
Locations
261 sites in 12 countries. Site status is shown where the registry gives one.
Local Institution - 005-164
Birmingham, Alabama
Clearview Cancer Institute - Huntsville
Huntsville, Alabama
Palo Verde Cancer Specialists - Glendale
Glendale, Arizona
The Oncology Institute of Hope & Innovation - Tucson
Tucson, Arizona
Yuma Regional Medical Center
Yuma, Arizona
Local Institution - 005-174
Jonesboro, Arkansas
NEA Baptist Fowler Family Center for Cancer Care
Jonesboro, Arkansas
Highlands Oncology Group - Springdale
Springdale, Arkansas
Comprehensive Blood and Cancer Center - Bakersfield
Bakersfield, California
Local Institution - 005-118
Beverly Hills, California
Local Institution - 005-171
Fresno, California
Providence Medical Foundation - Virginia K. Crosson Cancer Center - Fullerton
Fullerton, California
Local Institution - 005-096
Long Beach, California
Cancer and Blood Specialty Clinic
Los Alamitos, California
Los Angeles Hematology Oncology Medical Group
Los Angeles, California
Local Institution - 005-185
Los Angeles, California
Local Institution - 005-072
Newport Beach, California
Local Institution - 005-109
Northridge, California
Local Institution - 005-177
Redlands, California
Local Institution - 005-112
Riverside, California
University of California San Francisco
San Francisco, California
Local Institution - 005-176
San Marcos, California
Local Institution - 005-192
Torrance, California
Local Institution - 005-090
West Covina, California
Local Institution - 005-105
Whittier, California
Local Institution - 005-097
Lafayette, Colorado
Eastern Connecticut Hematology and Oncology Associates
Norwich, Connecticut
Michael and Dianne Bienes Comprehensive Cancer Center
Fort Lauderdale, Florida
Local Institution - 005-120
Fort Myers, Florida
Memorial Regional Hospital
Hollywood, Florida
Watson Clinic Cancer and Research Center
Lakeland, Florida
Mount Sinai Health System
Miami Beach, Florida
Local Institution - 005-120E
Naples, Florida
Local Institution - 005-079
Ocala, Florida
Local Institution - 005-104
Orlando, Florida
SCRI - Florida Cancer Specialists - North Region Research Office
St. Petersburg, Florida
SCRI - Florida Cancer Specialists - Panhandle Research Office
Tallahassee, Florida
Local Institution - 005-154
West Palm Beach, Florida
University Cancer & Blood Center (UCBC) - Athens
Athens, Georgia
Local Institution - 005-146
Atlanta, Georgia
Showing 40 of 261 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.